SCHEMBL7586967

SCHEMBL7586967

N#Cc1c(Cl)c(-c2cncc(Br)c2)n2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
ALDH1A1 P00352 6/20 0.39
HPGD P15428 4/20 0.39
GAA P10253 3/20 0.39
GLA P06280 2/20 0.39
CYP11B2 P19099 8/20 0.38
KMT2A Q03164 6/20 0.38
LMNA P02545 4/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
CYP11B1 P15538 3/20 0.38
HTT P42858 2/20 0.38
NCOA3 Q9Y6Q9 2/20 0.38
PABPC1 P11940 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP3 P42574 1/20 0.36
NCOA1 Q15788 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7585453 0.82 CYP11B2 (0.53) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL7586224 0.76 MAP2K3 (0.37) KDM4EALDH1A1CYP11B2KMT2AMAPT
SCHEMBL7854138 0.71 RAB9A (0.39) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL7588953 0.70 CYP11B2 (0.58) KDM4EALDH1A1GAAGLACYP11B2
SCHEMBL7586428 0.70 CYP11B2 (0.57) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL7588829 0.68 RXFP1 (0.36) KDM4EALDH1A1HPGDGAACYP11B2
SCHEMBL7590158 0.67 CYP11B2 (0.56) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL25417102 0.62 KDM4E (0.53) KDM4EALDH1A1HPGDCYP11B2KMT2A
SCHEMBL30398147 0.62 KDM4E (0.53) KDM4EALDH1A1HPGDCYP11B2KMT2A
SCHEMBL1606066 0.62 CYP11B2 (0.68) ALDH1A1GAAGLACYP11B2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US disclosed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP disclosed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them TNF, IL2, ZC3HAV1 KDM4E 710/4885ALDH1A1 1762/4885HPGD 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.